drugset / Trial / NCT06311942

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

NCT06311942

Phase 4 Recruiting 300 enrolled Chen Xiaoping
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. What can be done to improve the surgical prognosis of this group of patients needs to be continuously explored.

Timeline

Start
2024-04-01
Primary completion
2027-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule
Subject fluorouracil Small molecule
Background Lenvatinib Small molecule Oral
Background Leucovorin Small molecule